Codagenix is a privately held, biotechnology company based in Stony Brook, New York. The company focuses on constructing live-attenuated viral vaccines against multiple targets using the company's proprietary technology platform, SAVE. Standing for Synthetic Attenuated Virus Engineering, the platform relies on synthetic biology and the rational 're-design' of a target virus' entire genome to yield a vaccine strain. The customization process uses software-based algorithms to 're-code' the genome of a target virus.
The company's product pipeline includes vaccines for influenza, respiratory syncytial virus (RSV), dengue, foot and mouth disease virus (FMDV), pathogenic E. Coli, and other targets.
Co-Founder, Senior Scientific Officer
J. Robert Coleman
Co-Founder & COO
Co-Founder, President, and Chief Scientific Officer
Xconomy: With $2M, Codagenix Becomes Accelerate LI's First VC-Backed Grad
Documentaries, videos and podcasts